drugset / Trial / NCT03071224
Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein
NaSingle-groupOpen-labelOther
Summary
The overall goal of this protocol is to evaluate \[18F\]MK-6240 (also known as \[18F\]MNI-946) a tau targeted radiopharmaceutical.
Timeline
- Start
- 2016-06
- Primary completion
- 2021-06-09
- Completion
- 2021-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-MK-6240 | Diagnostic / imaging agent | — | — |
| Subject | florbetapir F 18 | Diagnostic / imaging agent | — | — |